RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTIONREALITY SUPPS RESEARCH NOTES
Due diligence

Choosing a research peptide supplier after the 2025–2026 shutdowns

6 Oct 2026Reality Supps Research Desk3 min read

Peptide Sciences closed in March 2026 and at least seven other vendors went dark in eighteen months. The seven checks a researcher should run on any supplier before ordering.

The research-peptide supply market reorganized itself between mid-2025 and late 2026. Peptide Sciences, for years the largest United States vendor by traffic, discontinued sales on March 6, 2026. Amino Asylum went offline after a federal inspection in June 2025. Paradigm Peptides’ owners pleaded guilty in December 2025 and were sentenced the following July. Smaller vendors closed through 2026 as payment processors withdrew.

For a researcher the practical question is how to evaluate the suppliers that remain. These seven checks take about fifteen minutes.

1. Certificates per lot, from a named laboratory

Ask for the certificate for the specific lot being sold, not a representative certificate. It should name the laboratory, state the method (HPLC and mass spectrometry), carry a recent date, and be published as issued. A supplier that offers certificates “on request” is asking you to trust rather than verify.

2. Independent blind testing

A growing number of researchers rely on third-party programs that purchase vials anonymously and test them. A supplier whose lots have been blind-tested, with the results public, has passed a check it could not influence. A supplier with no blind-test history is unproven, not necessarily bad.

3. Card payment accepted

Card acceptance is a proxy for underwriting. A merchant account survives only if a processor has reviewed the business and its chargeback history. Suppliers that accept only cryptocurrency or peer-to-peer apps have usually lost that review, and the buyer carries all of the risk on an irreversible payment.

Look at the footer. A supplier that names its legal entity, a physical address and a working phone number can be held to its terms. One that offers a contact form and nothing else cannot.

5. Stated shipping and returns terms

Specific terms (“orders before 2 PM Eastern ship the same business day”; “sealed vials returnable within seven days”) indicate an operation that fulfills orders routinely. Vague terms indicate the opposite.

6. Copy that describes research, not results

Read two product pages. A supplier operating as a research supplier describes structure, origin and the models studied, and cites sources. One that describes results in people, offers dosing guidance, or sells administration supplies alongside compounds is advertising something other than research use, and has been the target of the regulatory actions of the last two years.

7. Time in operation

Twelve months of continuous operation after mid-2025 is now a meaningful signal. The vendors that closed did so for identifiable reasons: regulatory correspondence they did not answer, product that was not what the label said, or processors that withdrew. A supplier that has stayed open through that period has, at minimum, avoided those three.

A short checklist

Check Pass
Lot-specific certificate from a named lab, HPLC + MS Yes / No
Public blind-test results Yes / No / None yet
Card payment accepted Yes / No
Entity, address, phone in footer Yes / No
Specific shipping and returns terms Yes / No
Research-only copy, sourced, no dosing Yes / No
Twelve months of operation Yes / No

Five or more passes is a supplier worth trying with a small order. Fewer than four is a supplier to avoid regardless of price.

References

  • U.S. Food and Drug Administration, Warning Letters to research-peptide sellers, December 2024 through August 2026 (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters).
  • U.S. Department of Justice, Northern District of Indiana, United States v. Kawa and Stechkober (plea December 2025; sentencing July 30, 2026).
  • Eli Lilly and Company, press release on enforcement referrals and litigation concerning unapproved retatrutide sellers (August 12, 2026).
Research use only · Not for human or animal consumption · Not medical advice · This note summarizes published in-vitro and animal research and makes no claims about effects in humans.